

Supplementary information

Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics

In the format provided by
the authors and unedited

Supplementary information. Ongoing early-phase trials of novel therapeutic agents in gastric and gastroesophageal adenocarcinoma.

Trial Identifier	Trial Phase	Drug Tested	Drug Target	Mechanism of Action	Estimated Date of Completion	Class of Therapeutic Intervention
NCT06055439	I/II	CHM-2101	CDH17	Cadherin-17 (CDH17) targeting autologous CAR T-cell	2027-05	Adoptive cell therapy
NCT06134960	I	KD-496	CLDN18.2 NKG2DL	CLDN18.2/ Natural killer group 2D ligand (NKG2DL) bispecific CAR T-cells	2026-11	Adoptive cell therapy
NCT05035407	I	KK-LC-1 TCR	KK-LC-1	Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) TCR gene therapy	2026-04	Adoptive cell therapy
NCT05239143	I	P-MUC1C-ALLO1	MUC1-C	Mucin 1 C-terminal (MUC1-C) CAR T-cells	2039-04	Adoptive cell therapy
NCT06242470	I	Vobramitamab exatecan (MGC026)	B7-H3	B7-H3 targeting antibody with topoisomerase I inhibitor	2028-10	Antibody-Drug Conjugate
NCT06628310 (AndroMETa-GEA)	II	ABBV-400	C-Met	Receptor tyrosine kinase receptor for the hepatocyte growth factor (C-Met)-targeting antibody (telisotuzumab) with topoisomerase I inhibitor	2030-10	Antibody-Drug Conjugate
NCT06008054	II	BL-B01D1	EGFR HER3	EGFR-HER3 bispecific antibody with topoisomerase I inhibitor	2025-12	Antibody-Drug Conjugate
NCT05514717	I	XMT-2056	HER2	HER2 targeting antibody with stimulator of interferon genes protein (STING) agonist payload	2027-04	Antibody-Drug Conjugate
NCT06781983	I	IPH4502	Nectin-4	Nectin-4 targeting antibody with topoisomerase I inhibitor	2029-04	Antibody-Drug Conjugate
NCT06171789	I/II	PRO1107	PTK7	Protein Tyrosine Kinase 7 (PTK7) targeting antibody with MMAE (monomethyl auristatin E) payload	2027-02	Antibody-Drug Conjugate
NCT06469944 (MK-3475-06C/KEYMAKER-U06)	I/II	Sacituzumab tirumotecan (MK-2870) (SKB264)	TROP2	Trophoblast cell surface antigen 2 (TROP2) targeting antibody with topoisomerase I inhibitor	2029-04	Antibody-Drug Conjugate
NCT05411133	I	Cabotamig (ARB202)	CDH17 CD3	Bispecific antibody against Cadherin-17 (CDH17) and CD3	2025-08	Bispecific T-cell Engaging Antibody
NCT06005493	I/II	AZD5863	CLDN18.2 CD3	Bispecific Antibody against CLDN18.2 and CD3	2026-12	Bispecific T-cell Engaging Antibody
NCT06427941	I	BGB-B2033	GPC3 4-1BB	Bispecific antibody against Glypican-3 (GPC3) and 4-1BB (CD137)	2026-10	Bispecific T-cell Engaging Antibody
NCT06266299	I	KK2269	CD40 EpCAM	Bispecific antibody against CD40 and Epithelial cell adhesion molecule (EpCAM)	2027-12	Bispecific-Antibody
NCT05482893 (TWINPEAK Study)	I/II	Spevatamig (PT886)	CLDN18.2	Bispecific antibody against CLDN18.2 and CD47	2028-04	Bispecific-Antibody
NCT05964543	I/II	Q-1802	CLDN18.2 PD-L1	Bispecific antibody against CLDN18.2 and PD-L1	2025-08	Bispecific-Antibody
NCT05771584	II	AST 301	HER2	HER2 intracellular domain-encoding pDNA vaccine that induces HER2-specific T cell and antibody responses	2026-06	Cancer Vaccine

NCT05969041	I	MT-302	TROP2	Trophoblast cell surface antigen 2 (TROP2)-targeting mRNA-based in vivo CAR therapy	2028-08	In vivo gene-modified cell therapy
NCT06075849	I	PB-101	VEGF-A PIGF	VEGF-A and Placental Growth Factor (PIGF) decoy receptor	2025-01	Ligand-trap fusion protein
NCT05789069	I	HFB200603	BTLA	BTLA antagonist	2025-12	Monoclonal antibody
NCT05581004	I	RO7502175	CCR8	CCR8 antagonist	2026-08	Monoclonal antibody
NCT06131398	I	AMG 355	CCR8	CCR8 antagonist	2028-02	Monoclonal antibody
NCT05891171 (ARC-25)	I	AB598	CD39	CD39 antagonist	2026-03	Monoclonal antibody
NCT05143970 (CHANCES)	I	IPH5301	CD73	CD73 antagonist	2026-02	Monoclonal antibody
NCT06730750	I/II	BMS-986490	CEACAM5	CEACAM5 antagonist	2029-12	Monoclonal antibody
NCT04363801 (DisTinGuish)	II	DKN-01	DKK1	Dickkopf-1 (DKK1) antagonist, restores canonical Wnt/ β -catenin signaling	2025-12	Monoclonal antibody
NCT06380816	I/II	UCB4594	HLA-G	HLA-G antagonist	2029-11	Monoclonal antibody
NCT05267626	I/II	AU-007	IL-2R α (CD25)	IL-2 Receptor alpha (IL-2R α , CD25) targeting antibody which blocks IL-2 binding to CD25, redirects IL-2 to T-effector cells and NK cells	2025-09	Monoclonal antibody
NCT05277051	I	GSK4381562	PVRIG	Poliovirus receptor-related immunoglobulin (PVRIG) inhibitor	2028-09	Monoclonal antibody
NCT05238883	I	HFB200301	TNFR2	TNFR2 agonist	2026-12	Monoclonal antibody
NCT05708950	I/II	KVA12123	VISTA	V-domain Ig suppressor of T-cell activation (VISTA) inhibitor	2024-12 (still recruiting)	Monoclonal antibody
NCT06283121	II	BioTTT001 (BT-001)	Oncolytic virus	Oncolytic adenovirus 5 engineered for tumor-selective replication and local expression of non-secretory IL-12	2027-11	Oncolytic Virus
NCT06008925	I/II	VG161	Oncolytic virus	HSV-1 oncolytic virus with IL-12, IL-15, IL-15Ra and PD-L1 blocking payloads	2026-06	Oncolytic Virus
NCT05427487	I	IVX037	Oncolytic virus	Bio-selected oncolytic RNA virus (picornavirus)	2026-11	Oncolytic Virus
NCT06508307	I	GC001	Oncolytic virus	Oncolytic virus (vaccinia virus)	2025-06	Oncolytic Virus
NCT06586957	I	NKT3964	CDK2	CDK2 targeting PROTAC (Proteolysis Targeting Chimera) degrader	2029-05	PROTAC
NCT06710756	I/II	PSV359	FAP- α	Fibroblast activation protein-alpha (FAP- α) targeting Lead-212 radiopharmaceutical	2032-05	Radiopharmaceutical
NCT06617169	I	MNPR-101-PCTA-177Lu	uPAR	uPAR targeting Lutetium-177 radiopharmaceutical	2025-06	Radiopharmaceuticals
NCT05098132	I	STK-012 SyntheKine	IL-2R α / β (CD25/CD122)	PEGylated, engineered IL-2 cytokine partial agonist with IL-2R α / β bias	2027-10	Recombinant protein
NCT05592626 (START-001)	I/II	STAR0602	TCR V β	Selective TCR (T-cell receptor) V β (V β 6/V β 10) engager with IL-2-based co-stimulation	2026-10	Recombinant protein
NCT05253053	I/II	TT-00420	Aurora A/B, FGFR1/2/3, VEGFRs,	Aurora A/B, fibroblast growth factor receptors (FGFRs) 1/2/3, vascular endothelial growth factor receptors (VEGFRs), Janus kinase (JAK) 1/2, and colony stimulating factor 1	2024-12	Small-molecule inhibitor

			JAK1/2, and CSF1R	receptor (CSF1R) multi-kinase inhibitor		
NCT05438420	I/II	Q702	Axl, Mer, CSF1R	Axl/Mer/CSF1R selective tyrosine kinase inhibitor	2026-06	Small-molecule inhibitor
NCT05940844	I	OB-002	CCR5	CCR5 antagonist	2025-08	Small-molecule inhibitor
NCT06257264	I	BG-68501	CDK2	CDK2 inhibitor	2028-02	Small-molecule inhibitor
NCT06264921	I	NKT3447	CDK2	CDK2 inhibitor	2027-03	Small-molecule inhibitor
NCT05827614 (POTENTIATE)	I	BBI-355	CHK1	Selective checkpoint kinase 1 (CHK1) inhibitor	2027-09	Small-molecule inhibitor
NCT06399757	I/II	APL-5125	CK2a	Casein kinase II subunit alpha (CK2a) targeted, Wnt signaling inhibitor	2027-05	Small-molecule inhibitor
NCT05415098	I	APG-5918	EED	Ectodermal embryonic development (EED) inhibitor, to inhibit polycomb repressive complex 2 (PRC2) function	2025-09	Small-molecule inhibitor
NCT05944237	I/II	HTL0039732	EP4	E-type prostanoid receptor 4 (EP4) antagonist, to counter immunosuppressive effects of PGE ₂	2026-09	Small-molecule inhibitor
NCT06270706	I	PLN-101095	Integrin αvβ8 and αvβ1	Integrin αvβ8 and αvβ1 inhibitor, which prevents integrin-mediated activation of latent TGF-β in the tumor microenvironment	2025-12	Small-molecule inhibitor
NCT05187182	I	Emavuserti (CA-4948)	IRAK4	IRAK4 inhibitor	2028-06	Small-molecule inhibitor
NCT05902988	I/II	VLS-1488	KIF18A	KIF18A ATPase inhibitor; induces mitotic arrest and selective death of chromosomal instability-high cancer cells	2026-06	Small-molecule inhibitor
NCT06395519 (ERADIC8)	I	ETX-19477	PARG	Poly (ADP-ribose) glycohydrolase (PARG) inhibitor	2026-12	Small-molecule inhibitor
NCT06769425	I	HS-10502	PARP-1	Poly (ADP-ribose) polymerase-1 (PARP1)-specific selective inhibitor	2026-09	Small-molecule inhibitor
NCT06078670	I/II	Mefuparib (CVL218)	PARP-1/2	Poly (ADP-ribose) polymerase-1/2 (PARP1/2) inhibitor	2026-06	Small-molecule inhibitor
NCT06360354	I	AMG 193	PRMT	Protein arginine methyltransferase 5 (PRMT) inhibitor, induces synthetic lethality in methylthioadenosine phosphorylase (MTAP)-deleted tumor cells	2029-02	Small-molecule inhibitor
NCT05400122	I	Vactosertib (TEW-7197)	TGFBR1	TGFBR1 (transforming growth factor-beta receptor type 1) inhibitor	2026-01	Small-molecule inhibitor
NCT05768932	I	BAL0891	TTK/MPS1, PLK1	Threonine Tyrosine Kinase (TTK/MPS1) and Polo-Like Kinase 1 (PLK1) inhibitor	2026-03	Small-molecule inhibitor

This table summarizes selected phase I and II clinical trials evaluating emerging therapeutics in advanced gastric and gastroesophageal cancer. Data were compiled from ClinicalTrials.gov as of June 2025.

Abbreviations: ADC, antibody–drug conjugate; CAR, chimeric antigen receptor; CDK, cyclin-dependent kinase; TCR, T-cell receptor; IL, interleukin.